←
Mathieu Spaas15 posts
Mathieu Spaas avatar

Mathieu Spaas

@MathieuSpaas
◷ Joined September 2018▧ 3 Photos and videos
Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·10 Jul 2023

Absolutely, some more insight into overall disease burden is provided in the online supplements 🔎

Post attachment

Also, consider disease volume and velocity. If these are high, any therapy may have limited benefit. pubmed.ncbi.nlm.nih.gov/3359… If 7/45 pts had progression pre treatment, >2/3 were >1st line systemic tx, 50% had progression at 3 mos follow-up, it is likely a high risk cohort.

Post attachment
Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

✅Conclusion: while safe, adding subablative multisite SBRT to anti-PD-(L)1 monotherapy did not result in a clinically meaningful benefit 🙏 Thank you to pts, families, trial staff and investigators for participating in this @komop_tgkanker and @VarianMedSys sponsored trial!

Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

With med FUP 12.5m: 👎 No benefit in terms of PFS: 💉 2.8m vs. ☢️ 4.4m (HR 0.95; p=.82) 👎 No improvement of OS: 💉 11.0m vs. ☢️ 14.3m (HR 0.82; p=.47) 🤷‍♂️Similar ORR, despite LCR 75% in irradiated pts 👍 NO increase in acute trAE of any grade or G3 or higher & NO G5 toxicity

Post attachment
Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

👥 >2/3 polyM+ pts and >1st line systemic Tx 😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness ☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes

Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020 ➡️Randomized 1:1 between 💉 anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions

Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

👥 >2/3 polyM+ pts and >1st line systemic Tx 😷 7/45 pts did not complete SBRT due to early PD or intercurrent illness ☢️ SBRT treated lesions were mostly 🫁 mets and lymph nodes

Mathieu Spaas avatar
Mathieu Spaas@MathieuSpaas·7 Jul 2023

This phase 2 RCT recruited n=99 with advanced melanoma, RCC, UC, HNSCC and NSCLC across 5 Belgian 🇧🇪 hospitals between 2018-2020 ➡️ Randomized 1:1 between 💉anti-PD-(L)1 alone or in combination with ☢️ SBRT 3x8Gy of up to 3 tumor lesions